Disease progression among 446 children with newly diagnosed type 1 diabetes located in Scandinavia, Europe, and North America during the last 27yr

Pediatric Diabetes

Volumn 15, Issue 5, 2014, Pages 345-354

  Max Andersen, Marie Louise ^a   Nielsen, Lotte B ^a   Svensson, Jannet ^a   Pörksen, Sven ^a   Hougaard, Philip ^b   Beam, Craig ^c   Greenbaum, Carla ^d   Becker, Dorothy ^e   Petersen, Jacob S ^f   Hansen, Lars ^a   Mortensen, Henrik B ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^f NOVO NORDISK A S   (Denmark)

Author keywords

C peptide; Children; Diabetes mellitus; Rate of decline; Type 1

Indexed keywords

C PEPTIDE; GLUTAMATE DECARBOXYLASE 65; INSULIN ANTIBODY; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2;

ARTICLE; BODY MASS; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; EUROPE; FEMALE; GEOGRAPHIC DISTRIBUTION; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NORTH AMERICA; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SCANDINAVIA; CAUCASIAN; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 1; INFANT; METABOLISM; MULTICENTER STUDY; PATHOPHYSIOLOGY; PRESCHOOL CHILD;

BODY MASS INDEX; C-PEPTIDE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INFANT; INSULIN ANTIBODIES; MALE; NORTH AMERICA; SCANDINAVIAN AND NORDIC COUNTRIES;

EID: 84904506208     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12098     Document Type: Article

References (36)

1. Sosenko JM, Palmer JP, Rafkin-Mervis L et al. Glucose and C-peptide changes in the perionset period of type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care 2008: 31: 2188-2192.
2. Sosenko JM, Palmer JP, Greenbaum CJ et al. Patterns of metabolic progression to type 1 diabetes in the diabetes prevention trial-type 1. Diabetes Care 2006: 29: 643-649.
3. Schatz D, Cuthbertson D, Atkinson M et al. Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus-a new surrogate measure of non-progression? Pediatr Diabetes 2004: 5: 72-79.
4. The DCCT Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial A randomized, controlled trial. Ann Intern Med 1998: 128: 517-523.
5. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003: 26: 832-836.
6. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987: 65: 30-36.
7. Knip M. Descriptive epidemiology of type 1 diabetes-is it still in? Diabetologia 2012: 55: 1227-1230.
8. The DIAMOND Project Group. Incidence and trends of childhood type-1 diabetes worldwide 1990-1999. Diabet Med 2006: 23: 857-866.
9. Patterson CC, Gyurus E, Rosenbauer J et al. Trends in childhood type 1 diabetes incidence in Europe during 1989-2008: evidence of non-uniformity over time in rates of increase. Diabetologia 2012: 55: 2142-2147.
10. Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 2006: 49: 20-24.
11. Wilkin TJ. The accelerator hypothesis: weight gain as the missing link between type I and type II diabetes. Diabetologia 2001: 44: 914-922.
12. de Onis M, Blossner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr 2010: 92: 1257-1264.
13. Wallensteen M, Dahlquist G, Persson B et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988: 31: 664-669.
14. Ortqvist E, Bjørk E, Wallensteen M et al. Temporary preservation of beta-cell function by diazoxide treatment in childhood type 1 diabetes. Diabetes Care 2004: 27: 2191-2197.
15. Mortensen HB, Swift PG, Holl RW et al. Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12months after diagnosis. Pediatr Diabetes 2010: 11: 218-226.
16. Andersen ML, Vaziri-Sani F, Delli A et al. Association between autoantibodies to the Arginine variant of the Zinc transporter 8 (ZnT8) and stimulated C-peptide levels in Danish children and adolescents with newly diagnosed type 1 diabetes. Pediatr Diabetes 2012: 13: 454-462.
17. Gottlieb PA, Quinlan S, Krause-Steinrauf H et al. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. Diabetes Care 2010: 33: 826-832.
18. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009: 361: 2143-2152.
19. Orban T, Bundy B, Becker DJ et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 1930: 378: 412-419.
20. Greenbaum CJ, Palmer JP, Nagataki S et al. Improved specificity of ICA assays in the Fourth International Immunology of Diabetes Serum Exchange Workshop. Diabetes 1992: 41: 1570-1574.
21. Savola K, Sabbah E, Kulmala P, Vahasalo P, Ilonen J, Knip M. Autoantibodies associated with type I diabetes mellitus persist after diagnosis in children. Diabetologia 1998: 41: 1293-1297.
22. Eckerbom S, Bergqvist Y, Jeppsson JO. Improved method for analysis of glycated haemoglobin by ion exchange chromatography. Ann Clin Biochem 1994: 31: 355-360.
23. Andersen E, Hutchings B, Jansen J, Nyholm M. Heights and weights of Danish children. Ugeskr Laeger 1982: 144: 1760-1765.
24. Nysom K, Molgaard C, Hutchings B, Michaelsen KF. Body mass index of 0 to 45-y-old Danes: reference values and comparison with published European reference values. Int J Obes Relat Metab Disord 2001: 25: 177-184.
25. Tim JC, Mary CB, Katherine MF, William HD. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000: 320.
26. Nordwall M, Ludvigsson1 J. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25years. Diabetes Metab Res Rev 2008: 24: 472-479.
27. Dabelea D, Rewers AB, Andrews JS et al. Temporal trends in the prevalence of ketoacidosis at diagnosis of Diabetes. The research for Diabetes in Youth study. Diabetes 2013: 62 (Suppl. 1280-OR): A72.
28. Meier JJ, Butler AE, Saisho Y et al. Beta|-cell replication is the primary mechanism subserving the postnatal expansion of beta-cell mass in humans. Diabetes 2008: 57: 1584-1594.
29. Gregg BE, Moore PC, Demozay D et al. Formation of a human beta-cell population within pancreatic islets is set early in life. J Clin Endocrinol Metab 2012: 97: 3197-3206.
30. Dabelea D, Mayer-Davis EJ, Andrews JS et al. Clinical evolution of beta cell function in youth with diabetes: the SEARCH for Diabetes in Youth study. Diabetologia 2012: 55: 3359-3368.
31. Bonfanti R, Bognetti E, Meschi F et al. Residual beta-cell function and spontaneous clinical remission in type 1 diabetes mellitus: the role of puberty. Acta Diabetol 1998: 35: 91-95.
32. Gottsäter A, Landin-Olsson M, Lernmark A, Fernlund P, Sundkvist G, Hagopian WA. Glutamate decarboxylase antibody levels predict rate of beta-cell decline in adult-onset diabetes. Diabetes Res Clin Pract 1995: 27: 133-140.
33. Nokoff NJ, Rewers M, Cree GM. The interplay of autoimmunity and insulin resistance in type 1 diabetes. Discov Med 2012: 13: 115-122.
34. Svensson J, Lyngaae-Joergensen A, Carstensen B, Simonsen LB, Mortensen HB, Danish Childhood DR. Long-term trends in the incidence of type 1 diabetes in Denmark: the seasonal variation changes over time. Pediatr Diabetes 2009: 10: 248-254.
35. Pundziute-Lycka A, Dahlquist G, Urbonaite B, Zalinkevicius R, on behalf of the Swedish and Lithuanian Childhood Diabetes Study Groups. Time trend of childhood type 1 diabetes incidence in Lithuania and Sweden, 1983-2000. Acta Paediatr 2004: 93: 1519-1524.
36. Dahlquist GG, Nystroem L, Patterson CC, the Swedish Childhood Diabetes Study Group, the Diabetes Incidence in Sweden Study Group. Incidence of type 1 diabetes in Sweden among individuals aged 0-34 years, 1983-2007: an analysis of time trends. Diabetes Care 2011: 34: 1754-1759.